Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sionna Therapeutics, Inc. (SION : NSDQ)

• Company Description    Sionna Therapeutics Inc. is a clinical-stage biopharmaceutical company by developing novel medicines that normalize the function of the CFTR protein. Sionna Therapeutics Inc. is based in BOSTON. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $34.71 Daily Weekly Monthly 20 Day Moving Average: 320,073 shares Shares Outstanding: 44.63 (millions) Market Capitalization: $1,549.06 (millions) Beta: 52 Week High: $43.20 52 Week Low: $7.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.98% 14.89% 12 Week 66.71% 59.80% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 21 HICKORY DRIVE SUITE 500 - WALTHAM,MA 02451 USA ph: 617-819-2020 fax: - ir@sionnatx.com http://www.sionnatx.com

• General Corporate Information    Officers Michael Cloonan - Chief Executive Officer; President Paul Clancy - Chairperson Elena Ridloff - Chief Financial Officer and Head of Corporate Deve Bruce Booth - Director H. Edward Fleming - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 829401108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 44.63 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,549.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -12.20% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -33.41 06/30/25 - -57.84 03/31/25 - -141.07 ROA 09/30/25 - -22.67 06/30/25 - -33.43 03/31/25 - -47.76 Current Ratio 09/30/25 - 25.61 06/30/25 - 35.33 03/31/25 - 28.73 Quick Ratio 09/30/25 - 25.61 06/30/25 - 35.33 03/31/25 - 28.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 7.29 06/30/25 - 7.62 03/31/25 - 7.97 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©